ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2288

Pregnancy Outcomes in Women Exposed to Golimumab

Suzan Esslinger1, Susan Gabriel 2, Marijo Otero-Lobato 3, Michael Clark 4, Pamela Sheridan 4 and Anja Geldhof 5, 1Janssen Biologics BV, Leiden, Netherlands, 2Janssen Rearch & Development, LLC, Horsham, PA, 3Janssen Biologics BV, Leiden, Zuid-Holland, Netherlands, 4Janssen Research & Development, LLC, Horsham, PA, 5Janssen Research & Development, LLC, Leiden, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Golimumab, pregnancy, psoriatic arthritis and ankylosing spondylitis (AS), Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: Reproductive Issues In Rheumatic Disorders Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and ulcerative colitis (UC). To characterize pregnancy outcomes in patients treated with GLM, data obtained from maternal exposure to GLM are presented.

Methods:

This dataset includes individual patient cases reported to the manufacturer through 06 April 2019. Cases included in the analysis were medically confirmed cases of maternal exposures to GLM during pregnancy or within 3 months prior to conception, and a reported pregnancy outcome. Both prospectively reported (ie, pregnancy outcome not known when first reported) and retrospectively reported cases (ie, pregnancy outcome known when first reported) were included. Cases originated from various sources, including spontaneous reporting, clinical studies, and registries.

Results: Two hundred eight pregnancy cases[1] (131 rheumatological[2]; 43 UC; and 34 other) with 211 reported birth outcomes were identified. Of these 208 pregnancy cases, 119 were prospective and 89 were retrospective (Table 1). Average maternal age was 31.9 years. Of the 119 prospectively reported pregnancy cases, 89 (74.8%) resulted in live births, 19 (16.0%) resulted in spontaneous abortion (of these, 42.1% (8/19) received GLM in combination with methotrexate [MTX]), 10 (8.4%) resulted in induced/elective abortion, and 1 (0.8%) resulted in ectopic pregnancy. Overall, 9 congenital anomalies were reported (2 prospective/7 retrospective cases).

For 183 of the 208 pregnancy cases with reported outcomes, the trimester of exposure to GLM was known (Table 2). Among the 110 prospectively reported cases, 82 (74.5%) were exposed during trimester 0 or 1. Of these, 19 had concomitant exposure to MTX, with the following birth outcomes: 8 live births, 8 spontaneous abortions, 3 elective/induced abortions. Eighteen of the prospectively reported cases (16.4%) were exposed to GLM throughout pregnancy (1st, 2nd and 3rd trimester) and all resulted in live births.

[1] Three cases reported twin pregnancies.

[2] Rheumatological includes rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Conclusion:

The rates of congenital malformations and spontaneous abortions were consistent with published background rates for the general population. Persistent exposure throughout pregnancy was rare, but not associated with apparent clinical sequelae. Limitations of this analysis include the lack of a direct comparison group, the variable amount of data available in the reports, and the possible bias towards reporting more negative outcomes in retrospective cases.


Table 1


Table 2


Disclosure: S. Esslinger, Johnson & Johnson, 3, 4; S. Gabriel, Johnson & Johnson, 1, 4; M. Otero-Lobato, Johnson & Johnson, 3, 4; M. Clark, Johnson & Johnson, 3, 4; P. Sheridan, Johnson & Johnson, 3, 4; A. Geldhof, Johnson & Johnson, 3, 4.

To cite this abstract in AMA style:

Esslinger S, Gabriel S, Otero-Lobato M, Clark M, Sheridan P, Geldhof A. Pregnancy Outcomes in Women Exposed to Golimumab [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pregnancy-outcomes-in-women-exposed-to-golimumab-2/. Accessed January 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-in-women-exposed-to-golimumab-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences